RALEIGH, N.C., Oct. 29, 2025 /PRNewswire/ -- GeneVentiv Therapeutics, Inc., a privately held biotechnology company developing one-time gene therapies for rare and inherited diseases, today announced ...
Highly competitive NIH program validates science, funds costly toxicology work, and accelerates progress toward IND for a one-time gene therapy for hemophilia A, with or without inhibitors RALEIGH, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results